openPR Logo
Press release

RNAi for Therapeutic Market Size, Soaring at 24 % CAGR to Register Reach 3580 million USD by 2024 - by Top Key Players: Alnylam Pharmaceuticals, Arbutus Biopharma (Tekmira), Arrowhead, Dicerna Pharmaceuticals, Mirna Therapeutics, Quark Pharmaceuticals, RX

02-15-2019 06:33 PM CET | Health & Medicine

Press release from: marketstudyreport.com

/ PR Agency: marketstudyreport
RNAi for Therapeutic Market

RNAi for Therapeutic Market

Recently, Market Study Report, LLC, documented a study on the RNAi for Therapeutic Market which encompasses significant inputs with respect to market share, market size, regional landscape, contributing players, and revenue projection of this industry vertical. The report also educates investors regarding the existing tends, prime challenges, and current expansion strategies applied by the key organizations that constitute the hyperactive competitive gamut of this business sphere.

The global RNAi for Therapeutic market is valued at 990 million in 2018 and is expected to reach 3580 million by the end of 2024, growing at a CAGR of 24.0% between 2019 and 2024.

Request a sample of this premium report at https://www.marketstudyreport.com/request-a-sample/1607370?utm_source=openpr.com&utm_medium=Abhijeet
Market Segment by Companies, this report covers

• Alnylam Pharmaceuticals
• Arbutus Biopharma (Tekmira)
• Arrowhead
• Dicerna Pharmaceuticals
• Mirna Therapeutics
• Quark Pharmaceuticals
• RXi Pharmaceuticals
• Silence Therapeutics
• Benitec Biopharma
• miRagen Therapeutics
• Sylentis
• Gradalis
• Sirnaomics
• Silenseed

RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. RNAi is now known as precise, efficient, stable and better than antisense technology for gene suppression.

RNAi for Therapeutic is in the development stage and there is no use in the market. The fastest research is Clinical phrase III, Such as QP1-1007, QO1-1002 of Quark Pharmaceuticals. The major technology of RNAi for Therapeutic is siRNA, miRNA and shRNA. SiRNA technology is the most popular, with the expenses market share of 85%, following SiRNA, miRNA is the second of 16% expenses market share in 2015.

At present, global expenses concentrates in US and Europe, US takes 80% market share and Europe takes 5% market share. There is A Few R & D Company in the world and the market concentration is high. The top5 (expenses in RNAi for Therapeutic) companies are Alnylam Pharmaceuticals, Arrowhead, Dicerna Pharmaceuticals, Gradalis, miRagen Therapeutics. The five companies occupy about 83% of the market share.

The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of RNAi for Therapeutic.Europe also play important roles in global market, with market size of xx million in 2019 and will be xx million in 2024, with a CAGR of xx%.

This report studies the RNAi for Therapeutic market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market and splits the RNAi for Therapeutic market by product type and applications/end industries.

Request a discount on standard prices of this premium report at https://www.marketstudyreport.com/check-for-discount/1607370?utm_source=openpr.com&utm_medium=Abhijeet

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

siRNA
miRNA
shRNA

Market Segment by Applications, can be divided into

Cancer
Cardiovascular
HBV
Other

Table of Contents
1 RNAi for Therapeutic Market Overview
2 Manufacturers Profiles
3 Global RNAi for Therapeutic Market Competition, by Players
4 Global RNAi for Therapeutic Market Size by Regions
5 North America RNAi for Therapeutic Revenue by Countries
6 Europe RNAi for Therapeutic Revenue by Countries
7 Asia-Pacific RNAi for Therapeutic Revenue by Countries
8 South America RNAi for Therapeutic Revenue by Countries
9 Middle East and Africa Revenue RNAi for Therapeutic by Countries
10 Global RNAi for Therapeutic Market Segment by Type
11 Global RNAi for Therapeutic Market Segment by Application
12 Global RNAi for Therapeutic Market Size Forecast (2019-2024)
13 Research Findings and Conclusion
14 Appendix

Complete report at https://www.marketstudyreport.com/reports/global-rnai-for-therapeutic-market-2019-by-company-regions-type-and-application-forecast-to-2024?utm_source=openpr.com&utm_medium=Abhijeet

About Us:

Marketstudyreport.com allows you to manage and control all corporate research purchases to consolidate billing and vendor management. You can eliminate duplicate purchases and customize your content and license management.

Contact Us:

Market Study Report LLC

4 North Main Street,

Selbyville, Delaware 19975

USA

Phone: 1-302-273-0910

US Toll Free: 1-866-764-2150

Email: sales@marketstudyreport.com

Website: https://www.marketstudyreport.com

Blog: https://www.marketstudyreport.com/blog

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release RNAi for Therapeutic Market Size, Soaring at 24 % CAGR to Register Reach 3580 million USD by 2024 - by Top Key Players: Alnylam Pharmaceuticals, Arbutus Biopharma (Tekmira), Arrowhead, Dicerna Pharmaceuticals, Mirna Therapeutics, Quark Pharmaceuticals, RX here

News-ID: 1593125 • Views:

More Releases from marketstudyreport.com

Load Bank Market Growth Prospectus by 2028 - Business Opportunities by ASCO Power Technologies (Schneider Electric), Simplex, Shenzhen Sikes, Pite Tech
Load Bank Market Growth Prospectus by 2028 - Business Opportunities by ASCO Powe …
A concise assortment of data on the 'Load Bank Market' offers an exhaustive study targeting current market trends influencing the business across assorted regions. Significant details related to market size, market share, applications, and statistics are put together to convey an ensemble prediction of the industry. The research further focuses on comprehensive competitor analysis in addition to highlighting growth strategies embraced by market leaders. Load Bank Market Size was estimated
Agriculture Equipment Market is Expected to Reach USD 161640 Million by 2028 - John Deere, CNH Industrial, Kubota, AGCO, Claas, Yanmar, Mahindra, LOVOL
Agriculture Equipment Market is Expected to Reach USD 161640 Million by 2028 - J …
Global Agriculture Equipment Market with respect to the pivotal drivers influencing the revenue graph of this business sphere. The current trends of the market with the geographical landscape, demand, remuneration scale, and growth of this vertical have also been included in this report. Global Agriculture Equipment Market Size was estimated at USD 114110 million in 2021 and is projected to reach USD 161640 million by 2028, exhibiting a CAGR of
Electric Vehicle Market Size to grow at a CAGR of 23.5% through 2028| Tesla Inc., Volkswagen AG, SAIC Motors, BYD Auto Co. Ltd., BMW Group, Nissan Motor Co. Ltd., Hyundai Group
Electric Vehicle Market Size to grow at a CAGR of 23.5% through 2028| Tesla Inc. …
Global Electric Vehicle Market with respect to the pivotal drivers influencing the revenue graph of this business sphere. The current trends of market with the geographical landscape, demand, remuneration scale, and growth of this vertical have also been included in this report. The electric vehicles (EVs) market is estimated to witness a robust growth rate of 23.5% during the period 2019-2028. The operation is done to stop ligament tears and
Fuel Cell Air Compressor Market is Expected to Reach USD 512.3 Million by 2028 - Garrett Motion, Hanon Systems, UQM Technologies, FISCHER Fuel Cell Compressor
Fuel Cell Air Compressor Market is Expected to Reach USD 512.3 Million by 2028 - …
Global Fuel Cell Air Compressor Market with respect to the pivotal drivers influencing the revenue graph of this business sphere. The current trends of market with the geographical landscape, demand, remuneration scale, and growth of this vertical have also been included in this report. Global Fuel Cell Air Compressor Market Size was estimated at USD 215.1 million in 2021 and is projected to reach USD 512.3 million by 2028, exhibiting

All 5 Releases


More Releases for RNA

Global RNA Analysis/Transcriptomics Market Report
The Global RNA Analysis / Transcriptomics Market is projected to expand at a CAGR of 12.5% during the forecast period, to hit USD 8.1 Billion by 2026, according to a recent market report compiled by Global Market Estimates. Due to the rising need for personalized medicines, the demand for RNA Analysis / Transcriptomics is expected to raise the market demand. Browse 156 Market Data Tables and 112 Figures spread through 175
Cancer RNA Expression Market to Reap Excessive Revenues by 2028(By sequencing te …
Worldwide cancer is one of the leading cause of death and effective way of treating it still looks unaccomplished in most parts of the world. The factors which influence the successful treatment of cancer are different depending on the stage of diagnosis, treatment availability and availability of trained healthcare professionals coupled with high economic burden of the disease. The gene expression of cancerous cells varies by cancer type and may
Senior experts from Exicure, Roche, GSK, BioNTech RNA Pharmaceuticals & MiNA The …
With less than 4 weeks until SMi’s 10th annual RNA Therapeutics event (http://www.therapeutics-rna.com/openpr) opens its doors in London, UK next month, registration will soon be closing and delegate places are becoming increasingly limited. Over the course of 2 focused days, attendees will be able to have an exclusive look into key developments in oligonucleotide therapeutics, mRNA technology, delivery mechanisms, and much more, led by industry leaders, scientific pioneers, and academics exploring
RNA Therapy Improves Vision in Child Blindness, hear more about recent developme …
SMi Reports: In light of recent developments in the field of RNA Therapy, SMi’s 10th Annual RNA Therapeutics is set to deliver the latest advancements in February this year. Leber congenital amaurosis (LCA), one of the most common causes of blindness in children, has been the subject of successful RNA therapy as researchers at the University of Pennsylvania recently published new data showing the success of the new therapy which improved
New Confirmed Delegates & Speakers for RNA Therapeutics
SMi are thrilled to welcome Dr. James Hamilton, Vice President, Head of Clinical Development, Arrowhead Pharmaceuticals onto the speaker panel RNA Therapeutics 2018! Dr. James Hamilton is currently responsible for all aspects of clinical trial design, implementation and execution. In this role, Dr. Hamilton managed the ARC-520 and ARC-AAT global programs through Phase 2 of development. Previously, Dr. Hamilton was Medical Director and Head of Corporate Development at Arrowhead. He led
Introducing the 9th Annual RNA Therapeutics 2018
As the requirement for targeted solutions for chronic diseases continues to grow, the interest of pharmaceutical and biotech companies has increasingly focused towards RNA therapeutics, such that by 2020, the RNA Therapeutics Market is predicted to attain $1.2 billion. One of the main challenges in RNA Therapeutics continues to be bridging the gap between in-vivo and in-vitro models, hear key case studies on the development on the latest delivery systems and